| Fietkau, Rainer |
| Completed | 3 | 830 | Europe | Induction chemotherapy with gemcitabine or FOLFIRINOX, all brands of gemcitabine and FOLFIRINOX components are allowed, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine, all brands of gemcitabine are allowed, Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy | University of Erlangen-Nürnberg Medical School | Pancreatic Cancer | 02/21 | 11/23 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 702 | Europe | Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin | Prof. Dr. med. Claus Rödel | Rectal Cancer Stage III | 09/23 | 09/28 | | |
NCT03697343: Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases |
|
|
| Recruiting | 3 | 382 | Europe | Radiosurgery, Fractionated stereotactic radiotherapy | University of Erlangen-Nürnberg Medical School | Cerebral Metastases of Solid Cancers | 05/26 | 05/26 | | |
DIREKHT2, NCT06030440: De-Intensification of Postoperative Radiotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck |
|
|
| Recruiting | 2/3 | 508 | Europe | Eliminating RT to the elective neck, RT standard of care | University of Erlangen-Nürnberg Medical School | Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Oropharynx | 12/31 | 09/33 | | |
FOKAL-BT, NCT02391051: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial |
|
|
| Recruiting | 2 | 50 | Europe | HDR-Brachytherapy | University of Erlangen-Nürnberg Medical School | Prostate Cancer | 12/19 | 12/29 | | |
| Completed | 2 | 120 | Europe | Durvalumab + Tremelimumab + RT | University of Erlangen-Nürnberg Medical School | Locally Advanced Head and Neck Squamous Cell Carcinoma | 09/21 | 02/24 | | |
| Active, not recruiting | 2 | 120 | Europe | Trabectedin, Yondelis, DNA double-strand breaks | Ludwig-Maximilians - University of Munich | Sarcoma | 08/23 | 08/23 | | |
| Completed | 2 | 115 | Europe | A (pembrolizumab+RT), Keytruda + RT, B (pembrolizumab), Keytruda | University of Erlangen-Nürnberg Medical School, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg | Head and Neck Squamous Cell Carcinoma | 10/24 | 10/24 | | |
NCT05433116: Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC |
|
|
| Recruiting | 2 | 50 | Europe | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Universität des Saarlandes | Head and Neck Squamous Cell Carcinoma | 09/25 | 09/26 | | |
HyRec, NCT01716949: Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer |
|
|
| Recruiting | 1/2 | 59 | Europe | Radiotherapy, Hyperthermia, 5-Fluorouracil, all brands of 5-Fluorouracil are allowed, Capecitabine, all brands of Capecitabine are allowed, Oxaliplatin, all brands of oxaliplatin are allowed | University of Erlangen-Nürnberg Medical School | Rectal Cancer | 06/22 | 06/23 | | |
ST-ICI, NCT03453892: Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition |
|
|
| Completed | N/A | 150 | Europe | Nivolumab, Pembrolizumab, Radiotherapy, Ipilimumab | University of Erlangen-Nürnberg Medical School | Metastatic Cancer | 02/21 | 12/22 | | |
NCT02022384: Immunophenotyping From Blood of Patients With Malignant Gliomas |
|
|
| Completed | N/A | 50 | Europe | Blood sample and life quality questionnaires | University of Erlangen-Nürnberg Medical School | Anaplastic Astrocytoma, Glioblastoma Multiforme | 12/21 | 12/22 | | |
GLIO-CMV-01, NCT02600065: Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy |
|
|
| Completed | N/A | 350 | Europe | Blood draw and MRI | University of Erlangen-Nürnberg Medical School | Cytomegalovirus Infections | 12/22 | 12/22 | | |
| Recruiting | N/A | 500 | Europe | TTFields | NovoCure Ltd. | Glioblastoma | 12/24 | 02/25 | | |
ST-ICI02, NCT04892849: Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy |
|
|
| Recruiting | N/A | 200 | Europe | Conventional Therapy acc. to prevailing clincal approved schemes | University of Erlangen-Nürnberg Medical School | HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Skin, Small Cell Bronchial Carcinomas | 05/26 | 12/27 | | |
IMMO-LDRT02, NCT05887284: Investigation of the Clinical Efficacy of Low-dose Ionizing Radiation in the Treatment of Osteoarthritis |
|
|
| Recruiting | N/A | 132 | Europe | low dose radiotherapy (0.5 Gy), mock radiation treatment, low dose radiotherapy (1.0 Gy) | University of Erlangen-Nürnberg Medical School, Johann Wolfgang Goethe University Hospital | Arthrosis, Osteoarthritis | 09/26 | 12/28 | | |
| Arnold |
| No trials found |
